Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis

Clinical Colorectal Cancer

Volumn 16, Issue 3, 2017, Pages e153-e163

  Tosi, Federica ^a   Magni, Elena ^a   Amatu, Alessio ^a   Mauri, Gianluca ^a   Bencardino, Katia ^a   Truini, Mauro ^a   Veronese, Silvio ^a   De Carlis, Luciano ^a,b   Ferrari, Giovanni ^a   Nichelatti, Michele ^a   Sartore Bianchi, Andrea ^a   Siena, Salvatore ^a,c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

BRAF; Colorectal cancer biomarkers; Colorectal cancer prognosis; KRAS; Liver metastases

Indexed keywords

B RAF KINASE; K RAS PROTEIN; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; COLORECTAL LIVER METASTASIS; GENE MUTATION; HUMAN; LIVER RESECTION; METASTASIS RESECTION; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; RECURRENCE FREE SURVIVAL; SYSTEMATIC REVIEW; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; GENETICS; LIVER TUMOR; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; SECONDARY;

COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS P21(RAS);

EID: 85012875416     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2017.01.004     Document Type: Article

References (73)

1. Ferlay, J., Soerjomataram, I., Dikshit, R., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136 (2015), E359–E386.
2. Meta-analysis Group in Cancer, Piedbois, P., Rougier, P., et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16 (1998), 301–308.
3. Kabbinavar, F.F., Hambleton, J., Mass, R.D., Hurwitz, H.I., Bergsland, E., Sarkar, S., Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 23 (2005), 3706–3712.
4. Van Cutsem, E., Köhne, C.-H., Láng, I., et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29 (2011), 2011–2019.
5. Heinemann, V., von Weikersthal, L.F., Decker, T., et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15 (2014), 1065–1075.
6. Venook, A.P., Niedzwiecki, D., Lenz, H.-J., et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol, 32, 2014, 5s (suppl; abstr LBA3). Available at: http://meetinglibrary.asco.org/content/126013-144. Accessed: November 26, 2016.
7. Loupakis, F., Cremolini, C., Masi, G., et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371 (2014), 1609–1618.
8. Van Cutsem, E., Cervantes, A., Adam, R., et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27 (2016), 1386–1422.
9. Adam, R., De Gramont, A., Figueras, J., et al. The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist 17 (2012), 1225–1239.
10. Bouviez, N., Lakkis, Z., Lubrano, J., et al. Liver resection for colorectal metastases: results and prognostic factors with 10-year follow-up. Langenbecks Arch Surg 399 (2014), 1031–1038.
11. Van Cutsem, E., Cervantes, A., Nordlinger, B., Arnold, D., ESMO Guidelines Working Group. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 25:suppl 3 (2014), iii1–iii9.
12. Primrose, J.N., Surgery for colorectal liver metastases. Br J Cancer 102 (2010), 1313–1318.
13. Kopetz, S., Chang, G.J., Overman, M.J., et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27 (2009), 3677–3683.
14. Hayashi, M., Inoue, Y., Komeda, K., et al. Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg, 10, 2010, 27.
15. Kopetz, S., Vauthey, J.N., Perioperative chemotherapy for resectable hepatic metastases. Lancet 371 (2008), 963–965.
16. Blazer, D.G., Kishi, Y., Maru, D.M., et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26 (2008), 5344–5351.
17. Chun, Y.S., Vauthey, J.-N., Boonsirikamchai, P., et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA 302 (2009), 2338–2344.
18. Shindoh, J., Loyer, E.M., Kopetz, S., et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol 30 (2012), 4566–4572.
19. Nordlinger, B., Guiguet, M., Vaillant, J.C., et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Française de Chirurgie. Cancer 77 (1996), 1254–1262.
20. Fong, Y., Fortner, J., Sun, R.L., Brennan, M.F., Blumgart, L.H., Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230 (1999), 309–318 discussion: 318-21.
21. Rees, M., Tekkis, P.P., Welsh, F.K., O'Rourke, T., John, T.G., Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247 (2008), 125–135.
22. Schmoll, H.J., Van Cutsem, E., Stein, A., et al. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23 (2012), 2479–2516.
23. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487 (2012), 330–337.
24. Van Cutsem, E., Köhne, C.-H., Hitre, E., et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360 (2009), 1408–1417.
25. Douillard, J.Y., Oliner, K.S., Siena, S., et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369 (2013), 1023–1034.
26. Lièvre, A., Bachet, J.-B., Le Corre, D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66 (2006), 3992–3995.
27. Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., et al. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67 (2007), 2643–2648.
28. Yaeger, R., Cowell, E., Chou, J.F., et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer 121 (2015), 1195–1203.
29. Kim, M.J., Lee, H.S., Kim, J.H., et al. Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer, 12, 2012, 347.
30. Cejas, P., López-Gómez, M., Aguayo, C., et al. KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One, 4, 2009, e8199.
31. Schirripa, M., Cremolini, C., Loupakis, F., et al. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer 136 (2015), 83–90.
32. Richman, S.D., Seymour, M.T., Chambers, P., et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27 (2009), 5931–5937.
33. Kadowaki, S., Kakuta, M., Takahashi, S., et al. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World J Gastroenterol 21 (2015), 1275–1283.
34. Tran, B., Kopetz, S., Tie, J., et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117 (2011), 4623–4632.
35. Yokota, T., Ura, T., Shibata, N., et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104 (2011), 856–862.
36. Cremolini, C., Di Bartolomeo, M., Amatu, A., et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol 26 (2015), 2092–2097.
37. Shimomura, M., Hinoi, T., Kuroda, S., et al. Overexpression of hypoxia inducible factor-1 alpha is an independent risk factor for recurrence after curative resection of colorectal liver metastases. Ann Surg Oncol 20:suppl 3 (2013), S527–S536.
38. Løes, I.M., Immervoll, H., Sorbye, H., et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. Int J Cancer 139 (2016), 647–656.
39. Karagkounis, G., Torbenson, M.S., Daniel, H.D., et al. Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 119 (2013), 4137–4144.
40. Huang, C.J., Teng, H.W., Chien, C.C., Lin, J.K., Yang, S.H., Prognostic significance of C-reactive protein polymorphism and KRAS/BRAF in synchronous liver metastasis from colorectal cancer. PLoS One, 8, 2014, e65117.
41. Sasaki, K., Margonis, G.A., Wilson, A., et al. Prognostic implication of KRAS status after hepatectomy for colorectal liver metastases varies according to primary colorectal tumor location. Ann Surg Oncol 23 (2016), 3736–3743.
42. Margonis, G.A., Kim, Y., Sasaki, K., et al. Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases. J Surg Oncol 114 (2016), 361–367.
43. Vauthey, J.N., Zimmitti, G., Kopetz, S.E., et al. RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258 (2013), 619–626 discussion: 626-7.
44. Schirripa, M., Bergamo, F., Cremolini, C., et al. BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection. Br J Cancer 112 (2015), 1921–1928.
45. Umeda, Y., Nagasaka, T., Mori, Y., et al. Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci 20 (2013), 223–233.
46. Teng, H.W., Huang, Y.C., Lin, J.K., et al. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 106 (2012), 123–129.
47. Stremitzer, S., Stift, J., Gruenberger, B., et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 99 (2012), 1575–1582.
48. Kemeny, N.E., Chou, J.F., Capanu, M., et al. KRAS mutation influences recurrence patterns in patients undergoing hepatic resection of colorectal metastases. Cancer 120 (2014), 3965–3971.
49. Petrowsky, H., Sturm, I., Graubitz, O., et al. Relevance of Ki-67 antigen expression and K-ras mutation in colorectal liver metastases. Eur J Surg Oncol 27 (2001), 80–87.
50. Isella, C., Mellano, A., Galimi, F., et al. MACC1 mRNA levels predict cancer recurrence after resection of colorectal cancer liver metastases. Ann Surg 257 (2013), 1089–1095.
51. Shoji, H., Yamada, Y., Taniguchi, H., et al. Clinical impact of c-MET expression and genetic mutational status in colorectal cancer patients after liver resection. Cancer Sci 105 (2014), 1002–1007.
52. Margonis, G.A., Spolverato, G., Kim, Y., Karagkounis, G., Choti, M.A., Pawlik, T.M., Effect of KRAS mutation on long-term outcomes of patients undergoing hepatic resection for colorectal liver metastases. Ann Surg Oncol 22 (2015), 4158–4165.
53. Shindoh, J., Nishioka, Y., Yoshioka, R., et al. KRAS mutation status predicts site-specific recurrence and survival after resection of colorectal liver metastases irrespective of location of the primary lesion. Ann Surg Oncol 23 (2016), 1890–1896.
54. Sterne, J.A., Sutton, A.J., Ioannidis, J.P., et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ, 343, 2011, d4002.
55. Egger, M., Davey Smith, G., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. BMJ 315 (1997), 629–634.
56. Brudvik, K.W., Kopetz, S.E., Li, L., Conrad, C., Aloia, T.A., Vauthey, J.N., Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases. Br J Surg 102 (2015), 1175–1183.
57. Nash, G.M., Gimbel, M., Shia, J., et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 17 (2010), 572–578.
58. Passiglia, F., Bronte, G., Bazan, V., Galvano, A., Vincenzi, B., Russo, A., Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis. Crit Rev Oncol Hematol 99 (2016), 150–157.
59. Vincenzi, B., Cremolini, C., Sartore-Bianchi, A., et al. Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients. Oncotarget 6 (2015), 31604–31612.
60. Andreyev, H.J., Norman, A.R., Cunningham, D., et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer 85 (2001), 692–696.
61. Deng, Y., Wang, L., Tan, S., et al. KRAS as a predictor of poor prognosis and benefit from postoperative FOLFOX chemotherapy in patients with stage II and III colorectal cancer. Mol Oncol 9 (2015), 1341–1347.
62. Price, T.J., Bruhn, M.A., Lee, C.K., et al. Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer 112 (2015), 963–970.
63. Koike, J., Ushigome, M., Funahashi, K., et al. Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer. Hepatogastroenterology 61 (2014), 2222–2226.
64. Loupakis, F., Moretto, R., Aprile, G., et al. Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer. Br J Cancer 114 (2016), 30–36.
65. Pietrantonio, F., Mazzaferro, V., Miceli, R., et al. Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases. Med Oncol, 32, 2015, 182.
66. Primrose, J., Falk, S., Finch-Jones, M., et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. Lancet Oncol 15 (2014), 601–611.
67. Kopetz, S., Overman, M.J., Chen, K., et al. Mutation and copy number discordance in primary versus metastatic colorectal cancer (mCRC). J Clin Oncol, 32, 2014, 5s (suppl; abstr 3509). Available at: http://meetinglibrary.asco.org/content/133539-144. Accessed: November 26, 2016.
68. Artale, S., Sartore-Bianchi, A., Veronese, S.M., et al. Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26 (2008), 4217–4219.
69. Misale, S., Yaeger, R., Hobor, S., et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486 (2012), 532–536.
70. Siravegna, G., Mussolin, B., Buscarino, M., et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med, 21, 2015, 827.
71. Sartore-Bianchi, A., Loupakis, F., Argilés, G., Prager, G.W., Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory. Ann Oncol 27 (2016), 1456–1466.
72. De Roock, W., Jonker, D.J., Di Nicolantonio, F., et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 304 (2010), 1812–1820.
73. Guinney, J., Dienstmann, R., Wang, X., et al. The consensus molecular subtypes of colorectal cancer. Nat Med 21 (2015), 1350–1356.